International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer's disease
Tian, Mei (Fudan University)
Civelek, A. Cahid (Johns Hopkins Medicine)
Carrió, Ignasi (Institut d'Investigació Biomèdica Sant Pau)
Watanabe, Yasuyoshi (RIKEN Center for Biosystems Dynamics Research)
Kang, Keon Wook (Seoul National University College of Medicine)
Murakami, Koji (Juntendo University Hospital)
Garibotto, Valentina (Geneva University Hospitals (Ginebra, Suïssa))
Prior, John O. (Lausanne University Hospital)
Barthel, Henryk (Leipzig University Medical Center)
Zhou, Rui (The Second Affiliated Hospital of Zhejiang University School of Medicine)
Hou, Haifeng (The Second Affiliated Hospital of Zhejiang University School of Medicine)
Dou, Xiaofeng (The Second Affiliated Hospital of Zhejiang University School of Medicine)
Jin, Chentao (The Second Affiliated Hospital of Zhejiang University School of Medicine)
Zuo, Chuantao (Fudan University)
Zhang, Hong (Zhejiang University)
Universitat Autònoma de Barcelona

Fecha:	2022
Resumen:	Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18 F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform 18 F-flortaucipir PET imaging. A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for 18 F-flortaucipir PET imaging in Alzheimer's disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. This international consensus and practice guideline will help to promote the standardized use of 18 F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Altres ; recerca ; Versió publicada
Materia:	18 F-flortaucipir ; Alzheimer's disease (AD) ; Positron emission tomography (PET) ; Brain imaging
Publicado en:	European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49 (january 2022) , p. 895-904, ISSN 1619-7089

DOI: 10.1007/s00259-021-05673-w
PMID: 34978595

10 p, 1021.0 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados